Alterity Therapeutics (NasdaqCM:ATHE) Conference March 24, 2026 10:00 PM ET Company ParticipantsDavid Stamler - CEO and Managing DirectorDavid StamlerGreat. Thank you, Melissa, and hello to everyone. Thank you for joining the presentation. I'm really excited to introduce you to Alterity. If you haven't heard of us before, we've got an exciting development program that is really gonna meet an important unmet need in treating this terrible disease. These are our forward-looking statements. As Melissa mentione ...

Core Viewpoint - Alterity Therapeutics is advancing ATH434 in late-stage clinical development for Multiple System Atrophy (MSA), a rapidly progressive neurodegenerative disease with no approved therapies [1][3] Company Overview - Alterity Therapeutics is a biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, particularly MSA and related Parkinsonian disorders [1][10] - The company is preparing to initiate a Phase 3 pivotal trial in MSA, having demonstrated clinically meaningful efficacy in a Phase 2 clinical trial [10] Disease Background - MSA is characterized by motor impairment, autonomic dysfunction, and rapid loss of independence, with symptoms resembling Parkinson's disease, making early diagnosis challenging [2][9] - The disease affects up to 50,000 individuals in the U.S., and there are currently no approved drugs to slow its progression or cure it [9] Clinical Development of ATH434 - ATH434 is an investigational oral therapy designed to redistribute excess iron in the brain, which contributes to neurodegeneration in MSA [3][6] - Positive results from a randomized, double-blind, placebo-controlled Phase 2 clinical trial showed robust clinical efficacy and a favorable safety profile [6][8] - The Phase 2 trial enrolled 77 adults and demonstrated significant improvement on the modified Unified Multiple System Atrophy Rating Scale (UMSARS) Part I compared to placebo [8] Research and Biomarkers - The clinical program incorporates biomarkers and advanced neuroimaging to better characterize disease progression and assess therapeutic impact [4] - Biomarkers indicated that both dose levels of ATH434 reduced iron accumulation in MSA-affected brain regions and showed trends in preserving brain volume [8] Awareness and Advocacy - Throughout MSA Awareness Month, the company will share educational information and highlight the experiences of the MSA community, emphasizing the need for continued research [5]

Exhibit 99.1 30 January 2026 Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update − Phase 2 Data Strengthened, Strong Cash Position, and Phase 3 Planning Well Advanced − Highlights MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 30 January 2026: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today released its Appendix 4C Quarterly Cash Flow Report and upda ...

Core Viewpoint - Alterity Therapeutics is advancing its ATH434 program for Multiple System Atrophy (MSA), with strengthened Phase 2 data and a solid cash position, while preparing for a pivotal Phase 3 clinical trial and engaging with the FDA [2][3][7]. Phase 2 Clinical Program & Regulatory Progress - The company has made significant progress in its Phase 2 trial for ATH434, with new analyses enhancing confidence in its potential as a disease-modifying therapy for MSA, projecting a commercial opportunity of US$2.4 billion [3][4]. - Preparations for an End-of-Phase 2 meeting with the FDA are underway, aimed at aligning on the design and requirements for a pivotal Phase 3 trial [5][9]. - A new analysis from the Phase 2 trial showed an improved efficacy signal in the 75 mg dose group, with a relative treatment effect increase from 30% to 35% compared to placebo [6]. Cash Position - As of December 31, 2025, the company reported a cash balance of A$49.2 million, with operating cash outflows of A$5.28 million for the quarter, providing a solid runway for regulatory and clinical objectives [21]. Corporate and Financial Update - The governance and leadership structure has been strengthened to support the transition into late-stage development, with key appointments made to enhance strategic execution [15][20]. - The company is exploring non-dilutive funding pathways for Phase 3 development through ongoing discussions with pharmaceutical partners [7][14]. Scientific and Clinical Engagement - Alterity has actively engaged with the global neurology community through scientific presentations, which are crucial for disseminating clinical data and refining interpretations of Phase 2 results [11][12]. - A Clinical Advisory Board meeting was held to review Phase 2 data and provide expert input for the Phase 3 trial design [12]. Outlook - The company is focused on advancing ATH434 toward a pivotal Phase 3 program, ensuring regulatory alignment with the FDA, and pursuing strategic partnerships to maximize long-term shareholder value [23].

Core Insights - Alterity Therapeutics has successfully completed its Phase 2 program for ATH434 in multiple system atrophy (MSA), demonstrating safety and efficacy, and is now preparing for Phase 3 trials [1][2][5] Company Developments - The Phase 2 trials showed ATH434 to be safe and well-tolerated, with significant efficacy signals in a market with no current disease-modifying treatments, representing a potential $2.4 billion opportunity [2][5] - The company is focused on advancing ATH434 towards a pivotal Phase 3 clinical program and is set to hold an End-of-Phase 2 meeting with the FDA in mid-2026 to finalize trial design [8][14] - Alterity has strengthened its leadership team, appointing Julian Babarczy as Chair of the Board and enhancing its governance structure to support growth [12][13] Clinical and Scientific Progress - ATH434 has shown promising results in slowing disease progression across various clinical endpoints, including functional measures and symptoms of orthostatic hypotension [5][11] - The company has deepened its understanding of MSA biology through biomarker and imaging studies, reinforcing the role of dysregulated brain iron and α-synuclein pathology [6][7] Future Objectives - The company aims to finalize its regulatory strategy for the Phase 3 trial, deepen engagement with the medical community, and build for scalable growth, including expanding intellectual property protection [18]

Summary of Alterity Therapeutics Conference Call Company Overview - **Company**: Alterity Therapeutics (NasdaqCM:ATHE) - **Focus**: Clinical stage company developing a novel drug candidate for multiple system atrophy (MSA) [1][2] Key Points Industry Context - **Disease**: Multiple system atrophy (MSA) is a serious neurodegenerative disorder with no approved therapies [3][4] - **Market Potential**: Significant market opportunity due to the lack of effective treatments, with an estimated peak sales potential of $2.4 billion globally for MSA treatment [15][28] Drug Development Progress - **Phase Two Trial**: Completed with results indicating that the drug (ATH-434) significantly slowed the decline of symptoms in MSA patients [1][5] - **Efficacy Data**: - Patients in the active treatment groups experienced a 30%-48% slower decline compared to placebo over 12 months [11] - Clinically meaningful treatment effects were observed, exceeding the threshold of 1.5 points on the Unified MSA Rating Scale [12][26] - **Safety Profile**: No significant safety signals were reported; adverse events were similar between active and placebo groups [13][14] Regulatory Designations - **Orphan Drug Designation**: Received in both the US and Europe, indicating the drug's potential to treat a rare disease [5] - **Fast-Track Designation**: Granted by the FDA, allowing for priority review and closer interaction with regulatory authorities [6] Future Development Plans - **Phase Three Preparation**: The company is actively preparing for the phase three trial, including completing non-clinical studies and engaging with the FDA [17][18] - **Timeline**: Anticipated end of phase two meeting with the FDA in the first quarter of next year [21] Commercial Insights - **Market Size**: Up to 50,000 patients in the US with MSA, though estimates vary [27] - **Physician Sentiment**: Over 70% of surveyed physicians expressed a strong likelihood to prescribe the drug if phase three data is positive [15][29] Financial Position - **Cash Reserves**: The company has over $50 million in cash, which is expected to support clinical and manufacturing activities leading up to phase three [30] Intellectual Property - **Patents Filed**: New patents filed to protect dosing ranges and clinical endpoints, as well as a patent related to the physical structure of the drug [31][32] Additional Insights - **Orthostatic Hypotension**: Recognized as a significant symptom of MSA, with the drug showing potential to stabilize or improve this condition [24][25] - **Unified MSA Rating Scale**: Considered crucial for assessing treatment efficacy, focusing on multiple domains affected by MSA [10][26] This summary encapsulates the critical aspects of Alterity Therapeutics' recent conference call, highlighting the company's advancements in drug development, regulatory progress, market potential, and financial health.

Core Insights - Alterity Therapeutics is focused on developing disease-modifying treatments for neurodegenerative diseases, particularly Multiple System Atrophy (MSA) [2][16] - The company reported positive clinical results for its lead asset, ATH434, and highlighted a potential market opportunity of approximately USD 2.4 billion for MSA treatments [4][13] Financial Overview - As of September 30, 2025, Alterity's cash position was A$54.56 million, with operating cash outflows of A$5.34 million for the quarter [5][9] - The company raised A$20 million in gross proceeds from a strategic placement to advance its programs [14] Clinical Development - Positive results from the ATH434-201 Phase 2 clinical trial showed a relative treatment effect of 35% in the 75 mg dose group at 52 weeks [8][10] - The ATH434-202 open-label trial demonstrated comparable efficacy to earlier-stage patients, confirming ATH434's favorable profile [10][16] - The company is engaging with the U.S. FDA to discuss data required for Phase 3 trials, with an End-of-Phase 2 meeting expected in mid-2026 [7][4] Regulatory and Market Engagement - ATH434 has received Fast Track Designation from the FDA, allowing for a series of Type C meetings to discuss necessary data for Phase 3 [6][7] - An independent commercial assessment indicated strong physician interest in ATH434, with over 70% of surveyed neurologists likely to prescribe it based on Phase 2 data [13] Research and Innovation - The company published findings from the bioMUSE Natural History Study, introducing the MSA Atrophy Index as a potential diagnostic tool for MSA [11] - Ongoing presentations at major conferences highlight the clinical progress and potential of ATH434 in treating MSA [12][16]

Core Insights - Alterity Therapeutics announced positive results from the ATH434-201 Phase 2 clinical trial for Multiple System Atrophy (MSA), demonstrating that ATH434 slows disease progression and stabilizes orthostatic hypotension [1][2] Group 1: Clinical Trial Results - The ATH434-201 trial involved 77 participants, comparing two doses of ATH434 (50 mg and 75 mg) against a placebo, with results indicating a 48% relative treatment effect at the 50 mg dose and a 30% effect at the 75 mg dose on the UMSARS I scale at 52 weeks [3][13] - A new analysis accounting for baseline differences in orthostatic hypotension (OH) showed a strengthened efficacy signal in the 75 mg group, with a relative treatment effect of 35% [5][13] - ATH434 demonstrated a beneficial effect on OH symptoms, with placebo patients worsening significantly while both treatment groups remained stable [5][7] Group 2: Neuroimaging and Biomarkers - The trial utilized advanced neuroimaging and biomarkers to refine MSA diagnosis and track disease evolution, showing that ATH434 reduced iron accumulation in affected brain regions [7][8] - Imaging biomarkers supported MSA diagnosis in 96.1% of participants, indicating a multimodal approach may enhance diagnostic accuracy [8][9] Group 3: Safety and Tolerability - ATH434 was well tolerated, with adverse event rates similar to placebo and no serious adverse events attributed to the drug [7][13] - The study also indicated increased outpatient activity levels in participants treated with ATH434, as measured by wearable sensors [7][13] Group 4: Company Overview - Alterity Therapeutics is focused on developing disease-modifying therapies for neurodegenerative diseases, with ATH434 being a lead candidate showing robust clinical efficacy in MSA [11][15] - The company has received Fast Track Designation and Orphan Drug Designation from the FDA for ATH434, highlighting its potential in treating MSA [11][15]

Core Insights - The data from the ATH434-201 Phase 2 clinical trial indicates that ATH434 slows disease progression and stabilizes orthostatic hypotension in patients with Multiple System Atrophy (MSA) [1][2] - New analyses presented at the MDS conference enhance confidence in the trial results, particularly regarding the efficacy of the 75 mg dose of ATH434 [2][3] - Advanced neuroimaging and biomarker analysis improve understanding of MSA diagnosis and disease tracking [1][7] Company Overview - Alterity Therapeutics is focused on developing disease-modifying treatments for neurodegenerative diseases, particularly MSA [1][14] - The company has demonstrated clinically meaningful efficacy for ATH434 in a randomized, double-blind, placebo-controlled Phase 2 clinical trial [14] - ATH434 has received Fast Track Designation and Orphan Drug Designation from the FDA for the treatment of MSA [10][14] Clinical Trial Details - The ATH434-201 trial involved 77 adults, randomized to receive either 50 mg or 75 mg of ATH434 or a placebo, administered twice daily for 12 months [12] - Results showed a 48% relative treatment effect at the 50 mg dose and a 30% relative treatment effect at the 75 mg dose on the modified UMSARS I scale at 52 weeks [3][12] - The trial also indicated that ATH434 was well tolerated, with similar adverse event rates compared to placebo [6][12] Efficacy and Safety Findings - ATH434 demonstrated a clinically significant reduction in disease severity on the UMSARS I scale, with improvements in daily living activities [3][6] - The treatment showed beneficial effects on orthostatic hypotension symptoms, with patients in the placebo group worsening while those on ATH434 remained stable [5][6] - Neuroimaging data indicated reduced iron accumulation in brain regions affected by MSA, suggesting target engagement [6][10] Diagnostic Advancements - The trial utilized state-of-the-art neuroimaging and biomarkers to refine MSA diagnosis and track disease evolution across its clinical phenotypes [2][7] - A multimodal approach combining α-synuclein aggregation profiles with clinical and imaging data may enhance diagnostic accuracy in MSA [7][8] - The study found a 90% concordance between clinical classification and quantitative MRI assessments, highlighting the value of imaging in diagnosis [8]

Core Insights - Alterity Therapeutics is set to present data from its ATH434-201 Phase 2 clinical trial for Multiple System Atrophy (MSA) at the 2025 International Congress of Parkinson's Disease and Movement Disorders [1][2] Company Overview - Alterity Therapeutics is a biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, particularly MSA and Parkinson's disease [4][8] - The company has demonstrated clinically meaningful efficacy for its lead asset, ATH434, in a randomized, double-blind, placebo-controlled Phase 2 clinical trial [8] ATH434 Details - ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins involved in neurodegeneration, specifically targeting α-synuclein pathology [4] - Preclinical studies have shown that ATH434 can reduce α-synuclein pathology and preserve neuronal function by restoring normal iron balance in the brain [4] - The drug has received Fast Track Designation and Orphan Drug Designation from the FDA for the treatment of MSA [4] ATH434-201 Phase 2 Clinical Trial - The ATH434-201 trial was a randomized, double-blind, placebo-controlled study involving 77 adults, assessing the efficacy, safety, and pharmacokinetics of ATH434 over 12 months [5][6] - Results indicated that ATH434 led to clinically and statistically significant improvements on the modified Unified Multiple System Atrophy Rating Scale (UMSARS) Part I compared to placebo [6] - Wearable sensors were used to evaluate motor activities, showing increased activity in outpatient settings for those receiving ATH434 [6] Presentation Details - The data will be presented in an oral session titled "ATH434 Slowed Disease Progression in a Phase 2 Study in Multiple System Atrophy" by CEO David Stamler on October 8, 2025 [3] - Additional poster presentations will cover topics such as the relationship between α-synuclein aggregation profiles and disease severity, and differences between clinical and imaging phenotypes in MSA [3]